A cohort study examining the risk of hepatitis B virus (HBV) reactivation in people living with HIV after switching to antiretroviral drugs (ARVs) that do not offer dual protection found that the overall risk was low, even among hepatitis B core Antibody-positive patients.
Rachel V. Denyer, MD, FRCP, of the Veterans Affairs Medical Center in Washington, D.C., and George Washington University, presented at the IDWeek 2023 conference, held in Boston, Massachusetts, October 11-14. One result.
However, new antiretroviral drugs introduced in the past decade, including dolutegravir-rilpivirine and the long-acting injectable cabotegravir-rilpivirine, are becoming the treatments of choice for people living with HIV; Discontinuation of medications such as norfovir, including nucleos